Legal status · Australia
Is UBT251 legal in Australia?
No. UBT251 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
UBT251 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Evidence level | Preliminary (research strength: Moderate) |
| Reviewed | Sep 2026 |
Classification and note come from the UBT251 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
UBT251 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What UBT251 is
Novo Nordisk's licensed triple agonist that produced up to 19.7% weight loss in 24 weeks in a Chinese Phase 2, the company's answer to retatrutide.
UBT251 was developed by The United Laboratories and licensed by Novo Nordisk outside China. 16%.
Mechanism: Agonism of GLP-1, GIP and glucagon receptors, combining appetite suppression with increased energy expenditure.
Regulatory history: Investigational; Phase 3 planned (China)
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for UBT251 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
UBT251 in other countries
Frequently asked questions
Is UBT251 legal in Australia?
No. UBT251 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Can I buy UBT251 in Australia?
No approved product exists to buy. In Australia UBT251 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is UBT251 TGA approved?
No. In Australia UBT251 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Investigational; Phase 3 planned (China). Evidence level: Preliminary.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for UBT251 live on its compound profile.
UBT251 profileThis page is general information about the regulatory status of UBT251 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.